MedTrace Logo

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

NCT07516132 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 850

Last updated 2026-07-01

No results posted yet for this study

Summary

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Conditions

  • Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG

OTX-TKI

Intravitreal Injection of OTX-TKI

Sponsors & Collaborators

  • Fortrea

    collaborator INDUSTRY

  • Duke Reading Center

    collaborator UNKNOWN

  • Ocular Therapeutix, Inc.

    lead INDUSTRY

Principal Investigators

  • Dilsher Dhoot, MD · California Retina Consultants (CRC)-Bakersfield

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-27
Primary Completion
2030-08-01
Completion
2030-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07516132 on ClinicalTrials.gov